Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Think Research Corporation THKKF


Primary Symbol: V.THNK

Healthcare Medical Devices
Think Research Corporation is a Canada-based company that offers digital health software solutions. It is a provider of cloud-based data, knowledge, and software solutions primarily delivered as software-as-a-service (SaaS) to healthcare delivery systems and the practitioners that they support. Its operations are organized into three lines of business: Software and Data Solutions, Clinical Research, and Clinical Services. Its SaaS solutions help patients find, navigate, and connect to health services across large governments and payer clients, while also ensuring safety for prescribed medications at pharmacies. Through its wholly owned subsidiary, BioPharma Services Inc., the Company provides research data and analysis derived from Phase I clinical trials, bioequivalence studies and bioanalytical services. Its clinics act as a test bed for its software and technology, transforming them with digital solutions that optimize clinical outcomes, streamline workflows, and optimize billing.


TSXV:THNK - Post by User

Think Research Corporation > Steven Takacsy officially BAD news!!
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(176)
•••
Comment by AlwaysLong683on Apr 25, 2022 5:04pm
112 Views
Post# 34630311

RE:Steven Takacsy officially BAD news!!

RE:Steven Takacsy officially BAD news!!
pacer217 wrote: In the last 16 months Steve recommended THNK as a TOP pick, BUY on weakness, PAST top pick
 SEVEN times!!!
On five of those I bought shares, and on five occasions - got stopped out at a loss!

Today was the last time!  STOPPED again @ .94.

Yeah it will; probably recover now!!


Key thing to remember with Takacsy or any other Fund Manager / BNN Guest is, if you are intrigued by a stock he / she mentions, use it as a STARTING POINT and take some time to do your own due diligence before making a decision on the name.

Takacsy has been bullish not only on THNK, but also BYL, DOC, and MDF over the past year or more Take a look at their 1-year stock price charts and see what disasters they've all been, even when compared to other Canadian small cap tech stocks in what has been a pretty bad year for the sector in general. I invested in MDF at around 14.00 over a year ago after listening to Takacsy but got out around 11.00 after I realized I made a mistake. It closed today at 2.55.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities